Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Del Prato, Steven E. Kahn, Imre Pávó, et al.
The Lancet (2021) Vol. 398, Iss. 10313, pp. 1811-1824
Closed Access | Times Cited: 434

Showing 1-25 of 434 citing articles:

Tirzepatide Once Weekly for the Treatment of Obesity
Ania M. Jastreboff, Louis J. Aronne, Nadia N. Ahmad, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 3, pp. 205-216
Open Access | Times Cited: 1681
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetes Care (2022) Vol. 45, Iss. 11, pp. 2753-2786
Open Access | Times Cited: 1145
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Melanie J. Davies, Vanita R. Aroda, Billy S. Collins, et al.
Diabetologia (2022) Vol. 65, Iss. 12, pp. 1925-1966
Open Access | Times Cited: 670
Type 2 diabetes
Ehtasham Ahmad, Soo Lim, Roberta Lamptey, et al.
The Lancet (2022) Vol. 400, Iss. 10365, pp. 1803-1820
Closed Access | Times Cited: 557
Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes
Dominik Dahl, Yukiko Onishi, Paul Norwood, et al.
JAMA (2022) Vol. 327, Iss. 6, pp. 534-534
Open Access | Times Cited: 357
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S158-S178
Open Access | Times Cited: 314
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
Louis J. Aronne, Naveed Sattar, Deborah B. Horn, et al.
JAMA (2023) Vol. 331, Iss. 1, pp. 38-38
Open Access | Times Cited: 246
Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis
Naveed Sattar, Darren K. McGuire, Imre Pávó, et al.
Nature Medicine (2022) Vol. 28, Iss. 3, pp. 591-598
Open Access | Times Cited: 239
Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Chengxu Ma, Xiaoni Ma, Conghui Guan, et al.
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 227
GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes
Nikolaus Marx, Mansoor Husain, Michael Lehrke, et al.
Circulation (2022) Vol. 146, Iss. 24, pp. 1882-1894
Open Access | Times Cited: 214
Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity
Sean Wharton, Thomas Blevins, Lisa Connery, et al.
New England Journal of Medicine (2023) Vol. 389, Iss. 10, pp. 877-888
Closed Access | Times Cited: 208
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Thomas Karagiannis, Ioannis Avgerinos, Aris Liakos, et al.
Diabetologia (2022) Vol. 65, Iss. 8, pp. 1251-1261
Open Access | Times Cited: 184
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Qingyang Shi, Kailei Nong, Per Olav Vandvik, et al.
BMJ (2023), pp. e074068-e074068
Open Access | Times Cited: 165
Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial
Hiddo J.L. Heerspink, Naveed Sattar, Imre Pávó, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 11, pp. 774-785
Open Access | Times Cited: 159
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Tamer Coşkun, Shweta Urva, William C. Roell, et al.
Cell Metabolism (2022) Vol. 34, Iss. 9, pp. 1234-1247.e9
Open Access | Times Cited: 158
Hypertension as Cardiovascular Risk Factor in Chronic Kidney Disease
Michel Burnier, Aikaterini Damianaki
Circulation Research (2023) Vol. 132, Iss. 8, pp. 1050-1063
Closed Access | Times Cited: 140
Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial
Nobuya Inagaki, Masakazu Takeuchi, Tomonori Oura, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 9, pp. 623-633
Closed Access | Times Cited: 136
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials
Mihaela-Simona Popoviciu, Lorena Păduraru, Galal Yahya, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 13, pp. 10449-10449
Open Access | Times Cited: 104
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 103
Pharmacotherapy of type 2 diabetes: An update and future directions
Antea DeMarsilis, Niyoti Reddy, Chrysoula Boutari, et al.
Metabolism (2022) Vol. 137, pp. 155332-155332
Closed Access | Times Cited: 95
Tirzepatide: First Approval
Yahiya Y. Syed
Drugs (2022) Vol. 82, Iss. 11, pp. 1213-1220
Closed Access | Times Cited: 86
Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial
Takashi Kadowaki, Rina Chin, Akichika Ozeki, et al.
The Lancet Diabetes & Endocrinology (2022) Vol. 10, Iss. 9, pp. 634-644
Open Access | Times Cited: 85
Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS‐CVOT design and baseline characteristics
Stephen J. Nicholls, Deepak L. Bhatt, John B. Buse, et al.
American Heart Journal (2023) Vol. 267, pp. 1-11
Open Access | Times Cited: 84
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff, Robert F. Kushner
Annual Review of Medicine (2023) Vol. 74, Iss. 1, pp. 125-139
Open Access | Times Cited: 80
Page 1 - Next Page

Scroll to top